Bird & Bird ATMD advises Zhejiang Taimei Technology Co., Ltd as Singapore counsel for its IPO listing on HKEX
Contacts
Partner
Singapore
We understand clients' needs, local markets, different business cultures.
Partner
Singapore
I am a Partner in our Corporate and Commercial Group in Singapore. I am involved in a wide range of corporate matters across various sectors, with a focus on corporate finance as well as mergers and acquisitions.
Associate
Singapore
I am an associate in Bird & Bird ATMD's Corporate & Commercial Group, based in Singapore. My key areas of practice include equity capital markets and mergers and acquisitions.
Bird & Bird ATMD has advised Zhejiang Taimei Technology Co., Ltd (“Taimei Technology”), a drug research and development digital intelligence solutions provider, as Singapore counsel for its initial public offering (IPO) to list on the Hong Kong Stock Exchange.
Taimei Technology raised HK$335 million under the IPO at the upper limit offer price of HK$13 apiece. The shares listed on 8 October 2024.
Taimei Technology has served over 1,400 pharmaceutical companies and clinical research organisations. Based on the number of clients, Taimei Technology is the most widely adopted digital solutions provider in China’s pharmaceutical R&D and marketing sectors.
The Bird & Bird ATMD team included corporate partner Marcus Chow and counsel Jolie Giouw and associate Tan Xing Yi.